

*CURRICULUM VITAE*

David G. Miller, MD

OFFICE ADDRESSES Retina Associates of Cleveland, Inc.  
3401 Enterprise Parkway, Suite 300; Cleveland, Ohio 44122  
14601 Detroit Avenue, Suite 200; Cleveland, Ohio 44107  
18660 Bagley Road, Suite 504; Cleveland, Ohio 44130  
5390 Belmont Avenue; Youngstown, Ohio 44505  
1 Park West, Suite 150; Akron, Ohio 44320  
3919 E. Market Street; Warren, Ohio 44484  
9485 Mentor Avenue, Suite 211; Mentor, Ohio 44060  
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052  
2235 East Pershing Street, Suite B; Salem, Ohio 44460

TELEPHONE 216-831-5700

EDUCATION

*College* The Ohio State University  
Columbus, Ohio  
1985-1989, BS (Chemistry)

*Medical School* University of Cincinnati  
Cincinnati, Ohio  
1989-1993, MD

POSTGRADUATE TRAINING

*Internship* Medicine  
University Hospital  
Cincinnati, Ohio  
1993-1994

*Residency* Ophthalmology  
Indiana University Medical Center  
Indianapolis, Indiana  
1994-1997  
Chief Resident, 1996-1997

*Fellowship* Vitreo-Retinal Surgery and Disease Fellowship  
Massachusetts Eye and Ear Infirmary  
Harvard Medical School  
Boston, Massachusetts  
1997-1998

## LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio

Diplomate, American Board of Ophthalmology, 1999

## PROFESSIONAL POSITIONS

Retina Associates of Cleveland, 1998-

Practice limited to retinal diseases and surgery. Associates: Lawrence J. Singerman, MD; Michael A. Novak, MD; Hernando Zegarra, MD; Z. Nicholas Zakov, MD; Scott D. Pendergast, MD; Joseph M. Coney, MD

Ohio Eye Injury Registry

Chairman, 2002-

Scientific reviewer

*Retina, The Journal of Retinal and Vitreous Diseases*

## ACADEMIC AND TEACHING ACTIVITIES

Chief Teaching Resident, Indiana University Medical Center, Department of Ophthalmology; 1996-1997

Medical student lectures and testing, grand rounds scheduling, guest speakers, interdepartmental education

Medical Biochemistry Recitation Leader, University of Cincinnati; 1990-1991

Biochemical problem-solving guidance for first-year medical students

Research Intern, National Institutes of Health, Bethesda, Maryland; 1989

Biochemical studies concerning ozone oxidation of proteins

## PROFESSIONAL SOCIETIES AND COMMITTEES

Cleveland Ophthalmological Society

President, 2004-2005

President-elect, 2003-2004

Vice President, 2002-2003

Treasurer, 2000-2002

Diabetic Retinopathy Clinical Research Network Group

Protocol Development Committee, 2005-

Scientific Reviewer, *Survey of Ophthalmology*

Scientific Reviewer, *Journal of Cataract and Refractive Surgery*

## HONORS AND AWARDS

Member, Phi Beta Kappa

The Ohio State University

Summa cum laude with Honors in the Liberal Arts

Outstanding Senior in Chemistry Award

Phi Beta Kappa

Ohio Regents Scholar

Ohio State University Distinguished Scholar

President's Award for Excellence in Scholarship

University of Cincinnati College of Medicine

Alpha Omega Alpha Medical Honor Society, junior year inductee

Medical Student Research Award

College of Medicine Merit Award

James R. Nicholl Memorial Scholar

## MEMBERSHIPS

Alpha Omega Alpha Medical Honor Society

American Academy of Ophthalmology

American Eye Study Club

American Medical Association

American Society of Vitreoretinal Specialists (formerly the Vitreous Society)

Massachusetts Eye and Ear Infirmary Alumni Association

Ohio State Medical Association

Ohio Ophthalmological Society

Phi Beta Kappa

## HOSPITAL AFFILIATIONS

Lakewood Hospital

Cleveland Clinic Foundation

Parma Community Hospital

Hillcrest Hospital

Fairview Hospital

Lake Hospital System

Community Health Partners

EMH Regional Medical Center

## RESEARCH ACTIVITIES

### *NIH-funded Grants*

*Course of response to focal photocoagulation for diabetic macular edema* (Diabetic Retinopathy Clinical Research Network /NIH)  
Principal investigator, 2007-

*Evaluation of vitrectomy for diabetic macular edema* (Diabetic Retinopathy Clinical Research Network /NIH)  
Principal investigator, 2006-

*Intravitreal ranibizumab or triamcinolone acetonide in combination with laser photocoagulation for diabetic macular edema* (Diabetic Retinopathy Clinical Research Network /NIH)  
Co-investigator, 2007-

*Age-Related Eye Disease Study 2* (National Eye Institute/ NIH)  
Co-investigator, 2006-

*Phase 2 evaluation of anti-VEGF therapy for diabetic macular edema: bevacizumab (Avastin)* (Diabetic Retinopathy Clinical Research Network /NIH)  
Co-investigator, 2006-

*Phase 2 study of peribulbar triamcinolone acetonide for diabetic macular edema* (Diabetic Retinopathy Clinical Research Network /NIH)  
Co-investigator, 2005-

*Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study*  
Co-investigator, 2004-

*Randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema* (Diabetic Retinopathy Clinical Research Network /NIH)  
Co-investigator, 2004-

*Pilot study of laser photocoagulation for diabetic macular edema* (Diabetic Retinopathy Clinical Research Network /NIH)  
Co-investigator, 2003-

*Family Investigation of Nephropathy and Diabetes – FIND* (National Institute of Diabetes and Digestive and Kidney Diseases/NIH)  
Co-investigator/Study Ophthalmologist. 2000-

*Epidemiology of Diabetes Interventions and Complications Trial – EDIC* (National Institute of Diabetes and Digestive and Kidney Diseases/NIH)  
Co-investigator, 1998-

*Complications of Age-related Macular Degeneration Prevention Trial – Laser treatment of*

*drusen – CAPT* (National Eye Institute/ NIH)  
Co-investigator, 1998-2007

### **Other National Clinical Trials**

*A multicenter, randomized, placebo-controlled, double-masked, parallel group, dose-ranging clinical trial of intravitreal microplasmin in patients undergoing surgical vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial (ThromboGenics)*  
Principal investigator, 2007-

*COBALT: COmbining Bevasiranib And Lucentis Therapy. A phase III, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis®, compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration (AMD) (Opko)*  
Principal investigator, 2007-

*FVF3689g: A Phase IIIb, multicenter study to evaluate the safety and tolerability of ranibizumab in naïve and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) (Genentech)*  
Principal investigator, 2006-

*Protocol FVF3426g: An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age related macular degeneration (AMD) who have completed the treatment phase of a Genentech-sponsored ranibizumab study (Genentech)*  
Principal investigator, 2006-

*Cand5 Anti-VEGF RNAi Evaluation (CARE): Dose comparison of Cand5 for subfoveal choroidal neovascularization associated with wet age-related macular degeneration (Acuity Pharmaceuticals)*  
Principal investigator, 2005-

*An open label study for the evaluation of tolerability of four dose levels of Cand5 (RNA-interference) administered by single intravitreal injection in patients with wet age-related macular degeneration (Acuity Pharmaceuticals)*  
Principal investigator, 2005-

*The effect of ruboxistaurin on clinically significant macular edema in patients with diabetes mellitus, as assessed by optical coherence tomography (Eli Lilly & Company)*  
Principal investigator, 2005-

*A randomized, double-masked, placebo controlled, parallel group, multi-center, dose-ranging study of denufosol tetrasodium (INS37217) intravitreal injection in subjects with rhegmatogenous retinal detachment (Inspire Pharmaceuticals)*  
Principal investigator, 2004-2005

*Protocol FVF2587g: a Phase III, multicenter, randomized, double-masked, active treatment-*

*controlled study of the efficacy and safety of rhuFabv2 (ranibizumab) compared with verteporfin (Visudyne®) photodynamic therapy in subjects with predominantly classic neovascular age-related macular degeneration (Genentech)*

Principal investigator, 2003-2006

*Intravitreal Steroid Injection Studies (ISIS)*

Principal investigator, 2002-2006

*A masked, multicenter, randomized, controlled trial to assess the safety and efficacy of 700 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema*

Co-investigator, 2007-

*A study of ranibizumab injection in subjects with clinically significant with macular edema center involvement secondary to diabetes mellitus (RIDE) (Genentech)*

Co-investigator, 2007-

*Indocyanine green (ICG) angiographic evaluation of ranibizumab (Lucentis®) treatment of pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD)*

Co-investigator, 2007-

*OMEGA: A randomized, double-masked, dose-ranging, multi-center, phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration (Othera)*

Co-investigator, 2007-

*Denali: a 24-month randomized, double-masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with ranibizumab (Lucentis®) versus ranibizumab (Lucentis®) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (Novartis)*

Co-investigator, 2007-

*Phase II randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in age-related macular degeneration (Sirion Therapeutics)*

Co-investigator, 2007-

*Age-related Macular Degeneration: Detection of Onset of new Choroidal neovascularization (AMD DOC) study comparing preferential hyperacuity perimetry (PHP) with supervised Amsler grid in detecting AMD for earlier treatment in high-risk fellow eyes (Johns Hopkins)*

Co-investigator, 2007-

*Phase IV, open label, multicenter trial of maintenance intravitreal injections of Macugen® (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement (Eyeteck 1023) ([OSI] Eyeteck)*

Co-investigator, 2006-

*Efficacy and safety of intravitreal injection of Macugen for recent onset neovascular lesions of AMD (Pfizer)*

Co-investigator, 2006-

*Phase III, multicenter, masked, randomized, sham controlled trial to assess the safety and efficacy of DEX PS DDS (700 micrograms, 350 micrograms, or placebo) in the treatment of patients with diabetic macular edema (Allergan)*

Co-investigator, 2006-

*Macugen (pegaptanib sodium) for angioid streaks complicated by choroidal neovascular membrane*

Co-investigator, 2006-

*Macugen (pegaptanib sodium) for pathological myopia complicated by subfoveal choroidal neovascularization*

Co-investigator, 2006-

*Phase III, multicenter, masked, randomized, sham controlled trial to assess the safety and efficacy of DEX PS DDS (700 micrograms, 350 micrograms, or placebo) in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion (Allergan)*

Co-investigator, 2005-

*Protocol OT-551-002: a multi-center, double-masked, randomized, vehicle-controlled, parallel group evaluation of the safety and efficacy of OT-551 ophthalmic solution to prevent formation or delay progression of nuclear cataract formation in post-vitrectomy patients (Othera)*

Co-investigator, 2005-2007

*Ocular side effects of Cialis vs. Viagra vs. placebo (Eli Lilly & Company)*

Co-investigator, 2005-2006

*Natural and family history studies of macular telangiectasia (MacTel Foundation)*

Co-investigator, 2005-

*Interval Dose Evaluation of Anecortave Acetate (IDEAA) Study (Alcon)*

Co-investigator, 2005-

*Phase II, dose ranging, open-labeled, multi-center study to evaluate the safety and efficacy of combretastatin A4 phosphate for treating subfoveal choroidal neovascularization in subjects with pathologic myopia (OXiGENE)*

Co-investigator, 2005-2006

*A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin (Visudyne<sup>®</sup>) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne<sup>®</sup> plus intravitreal pegaptanib (Macugen<sup>®</sup>) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (Novartis)*

Co-investigator, 2005-2006

*Phase 4, randomized, active controlled, double-masked, single dummy, to compare the safety and efficacy of Macugen every 6 weeks plus sham PDT to Macugen every 6 weeks with PDT in patients with predominantly classic CNV (Eyeteck 1012) (Eyeteck Pharmaceuticals)*

Co-investigator, 2005-2006

*A Phase II randomized, double-masked, safety, efficacy, and pharmacokinetics study of Macugen vs. placebo given every 6 weeks for 30 weeks for vision loss due to macular edema secondary to CRVO (Eyeteck 1011) (Eyeteck Pharmaceuticals)*

Co-investigator, 2004-2006

*A Phase II prospective, randomized, double-masked, sham controlled, dose-ranging, multicenter trial to assess the effect of pegaptanib sodium on fovea thickening in patients with exudative subfoveal age-related macular degeneration (EyeTech 1009) (Eyeteck Pharmaceuticals)*

Co-investigator, 2004-2006

*A Phase 1/2, randomized, masked, single and multiple-dose, sequential dose-escalation study of the safety and efficacy of AG-013958 in subjects with subfoveal choroidal neovascularization associated with age-related macular degeneration (Pfizer)*

Co-investigator, 2004-2006

*Anecortave Acetate Risk-Reduction Trial (Alcon Laboratories)*

Co-investigator, 2004-

*Protein Kinase C  $\beta$  Inhibitor Study B7A-MC-MBDL. Reduction in the occurrence of center-threatening diabetic macular edema (Eli Lilly & Company)*

Co-investigator, 2004-

*Multicenter, open label, flexible-dose, parallel-group evaluation of the cataractogenic potential of quetiapine fumarate (Seroquel<sup>™</sup>) and risperidone (Risperdal<sup>™</sup>) in the long term treatment of patients with schizophrenia or schizoaffective disorder*

Co-investigator/Evaluating ophthalmologist, 2003-

*Visudyne Patient Registry*

Co-investigator, 2003-2007

*The Implantable Miniature Telescope (IMT<sup>™</sup>) in patients with central vision impairment associated with age-related macular degeneration or Stargardt's macular dystrophy (VisionCare Ophthalmic Technologies)*

Co-investigator, 2003-



*A randomized, double-masked, multi-center trial of the safety, tolerability and pharmacokinetics of 1 mg/eye and 3 mg/eye intravitreal injections of pegaptanib sodium (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (EyeTech 1006) (EyeTech Pharmaceuticals)*

Co-investigator, 2002-2006

*A Phase II randomized, controlled, double-masked, dose-finding, multi-center, comparative trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer), given every 6 weeks for 12 to 30 weeks to patients with clinically significant diabetic macular edema (CSME) involving the center of the macula (EyeTech 1005) (EyeTech Pharmaceuticals)*

Co-investigator, 2002-2003

*Oculex Study: A phase 2 randomized, multicenter, dose-ranging, controlled, parallel-group trial to assess the safety and effectiveness of dexamethasone posterior segment drug delivery system (DEX PS DDS<sup>®</sup>) in the treatment of persistent macular edema (Oculex Pharmaceuticals)*

Co-investigator, 2001-2003

*Fluocinolone Acetonide in Diabetic Macular Edema (FAME 4) Study: A multicenter, randomized, masked, controlled study to evaluate the safety and efficacy of Retisert<sup>™</sup>, an intravitreal fluocinolone acetonide implant, in the treatment of patients with diabetic macular edema (Bausch & Lomb)*

Co-investigator, 2001-2007

*Visudyne<sup>™</sup> Early Retreatment (VER) Study: Multicenter, randomized, parallel group, double-masked, controlled phase IIIb, 2-year study comparing the efficacy and safety of Visudyne<sup>™</sup> therapy with early retreatment to standard treatment in predominantly classic subfoveal choroidal neovascularization secondary to age-related macular degeneration (Novartis Ophthalmics/CIBA)*

Co-investigator, 2001-2003

*Phase II/III randomized, double-masked, controlled, dose-ranging, multicenter comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks in patients with age-related macular degeneration (EyeTech 1004) (EyeTech Pharmaceuticals)*

Co-investigator, 2001-2005

*Transpupillary thermotherapy for the treatment of subfoveal occult choroidal neovascular membranes in patients with age-related macular degeneration (Iridex)*

Co-investigator, 2000-2004

*Verteporfin in Age-related Macular degeneration (VAM) Study: Open-label, multicenter, safety study of the treatment of predominantly classic choroidal neovascularization secondary to age-related macular degeneration using photodynamic therapy with verteporfin for injection (Novartis Ophthalmics/CIBA)*

Co-investigator, 1999-2000

*Evaluation of safety and duration of efficacy of anecortave acetate sterile suspension versus placebo following a single sub-Tenon's injection for the inhibition of neovascularization in patients with exudative age-related macular degeneration (Alcon Laboratories)*

Co-investigator, 1998-2001

*Verteporfin in Photodynamic Therapy Study (Novartis Ophthalmics/CIBA)*

Co-investigator, 1998-2003

*Protein kinase C  $\beta$  inhibitor studies: Diabetic Macular Edema Study and Diabetic Retinopathy Study. (Eli Lilly & Company)*

Co-investigator, 1998-2002

*Metalloprotease inhibitor for subfoveal choroidal neovascular membranes in patients with macular degeneration (Agouron Pharmaceuticals)*

Co-investigator, 1998-2001

## SELECTED PRESENTATIONS AT LOCAL, NATIONAL, AND INTERNATIONAL MEETINGS AND SYMPOSIA

1. 25-gauge surgery for macular hole repair. American Eye Study Club, 50th Annual Meeting. Ritz Carlton Bachelor Gulch, Beaver Creek, Colorado. July 22-26, 2007.
2. Update on diabetic retinopathy: diagnosis and treatment. Optometric Retinal Update Seminar. Westlake, Ohio. July 17, 2007
3. Macular hole repair. Optometric Retinal Update Seminar. Beachwood, Ohio. February 15, 2007.
4. Results of surgical management of senile macular holes by 25-gauge trans-conjunctival sutureless vitrectomy compared to standard vitrectomy systems. Annual meeting of the American Society of Retina Specialists. Cannes, France. September 8-13, 2006.
5. Treating macular degeneration with ranibizumab (Lucentis). Optometric Retinal Update Seminar. Westlake, Ohio. August 10, 2006.
6. Vitrectomy surgery. Parma Community General Hospital Retinal Update. Parma, Ohio. March 21, 2006.
7. Angiography in macular degeneration: Avastin and Lucentis. Optometric Retinal Update Seminar. Beachwood, Ohio. February 9, 2006.
8. Pharmacotherapy for age-related macular degeneration. Michigan Ophthalmological Society. Detroit, Michigan. November 16, 2005.
9. Update on treatments for age-related macular degeneration. Buffalo Eye Club. Buffalo, New York. October 27, 2005.

10. Modern retinal imaging. Optometric Retinal Update Seminar. Westlake, Ohio. August 11, 2005
11. Flashes & floaters. Optometric Retinal Update Seminar. Beachwood, Ohio. February 15, 2005
12. Cataract surgery and retinal disease. Optometric Retinal Update Seminar. Westlake, Ohio. July 29, 2004.
13. Retinal detachment: principles and treatment. Ohio Ophthalmological Society Annual Meeting. March 20, 2004.
14. Cataract surgery and macular disease. Ohio Ophthalmological Society Annual Meeting. March 20, 2004.
15. Photodynamic therapy and macular degeneration. Optometric Continuing Medical Education. Vermilion, Ohio. December 2003.
16. Retinal complications of toxoplasmosis retinitis. Cleveland Ophthalmological Society. Cleveland, Ohio. October 2003
17. Update on diabetic retinopathy. East-West Eye Conference. Cleveland, Ohio. October 2003.
18. Cataract surgery and retinal diseases. Cleveland Ophthalmological Society. Cleveland, Ohio. October 2003.
19. Pharmacotherapy of treatment of diabetic retinopathy. Optometric Retinal Update Seminar. Westlake, Ohio. August 12, 2003.
20. Implantable miniature telescope. Optometric Retinal Update Seminar. Beachwood, Ohio. February 20, 2003.
21. Update on macular degeneration. Cuyahoga Community College Encore Campus. Cleveland, Ohio. November 1, 2002.
22. Posterior segment complications and other challenges of LASIK in the high myope (with Mohinder K. Gupta, MD, co-instructor). American Society of Cataract and Refractive Surgery. Philadelphia, Pennsylvania. June 4, 2002.
23. Intravitreal triamcinolone acetonide for the treatment of macular edema. Cleveland Ophthalmological Society. Cleveland, Ohio. February 12, 2002.
24. The future of retinal care. Ohio Optometric Society. The Symposium of the Future. Cleveland, Ohio. February 4, 2002.

25. The myopic retina. Optometric Refractive Surgery Society, 6<sup>th</sup> Annual Symposium; August 2001. 1) Update on Diabetic Retinopathy; 2) Update on Age-related Macular Degeneration; and 3) Retinal Complications of High Myopia. Society for Excellence in Eyecare Conference; Aruba. January 27-31, 2002.
26. Update on photodynamic therapy with Visudyne. State University of New York, Visiting Professor. May 2001.
27. Unusual presentation of posterior scleritis. Cleveland Ophthalmological Society. Cleveland, Ohio. 2001.
28. Controversy in the management of posterior segment trauma. Cleveland Ophthalmological Society. Cleveland, Ohio. 2000.
29. Surgical management of macular hole. East-West Eye Conference. Cleveland, Ohio. 1999.
30. What's new in macula. East-West Eye Conference; Cleveland, Ohio, 1999.
31. Update on the management of age-related macular degeneration. East-West Eye Conference. Cleveland, Ohio. 1999.
32. Treatment of macular hole. Massachusetts Eye and Ear Infirmary Seminar, Surgical Advances in Ophthalmology. 1998.
33. Presumed ocular histoplasmosis syndrome and corticosteroids. Indiana University. 1997.
34. The use of corticosteroids in the treatment of histoplasmosis-related subfoveal choroidal neovascularization. Association for Research and Vision in Ophthalmology. Fort Lauderdale. Florida, 1997.
35. Patient satisfaction with orbicectomy in the treatment of blepharospasm. Indiana University, 1996.

## PUBLICATIONS

### *Journal Articles*

1. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. *Ophthalmology* 2007;114:1860-1867.
2. Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. *Am J Ophthalmol* 2007;144:454-456.
3. Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in

- patients with neovascular age-related macular degeneration. *Ophthalmology* 2007; 114:1702-1712.
4. Diabetic Retinopathy Clinical Research Network. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. *Ophthalmology* 2007;114:1190-1196.
  5. Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. *Ophthalmology* 2007;114:525-536.
  6. Diabetic Retinopathy Clinical Research Network. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. *Ophthalmology* 2007; 114:520-525.
  7. Diabetic Retinopathy Clinical Research Network. Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. *Arch Ophthalmol* 2007;125:469-480.
  8. Russell SR, Hudson HL, Jerdan JA; Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes. *Surv Ophthalmol* 2007;52 Suppl 1:S79-90.
  9. Miller DG, Singerman LJ. Vision loss in younger patients: a review of choroidal neovascularization. *Optom Vis Sci*;83:316-325, 2006.
  10. Diabetic Retinopathy Clinical Research Network, Danis RP, Glassman AR, Aiello LP, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Kinyoun JL, Murtha TJ, Topping TM, Shami M, Sharuk GS, Wells JA 3<sup>rd</sup>. Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. *Arch Ophthalmol* 2006;124:1701-1707.
  11. Complications of Age-related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: The Complications of Age-Related Macular Degeneration Prevention Trial. *Ophthalmology* 113:1974-1986, 2006.
  12. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. *Ophthalmology* 2006;113:1508-1521.
  13. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. *Ophthalmology* 2006;113:992-1001.

14. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N Engl J Med* 355:1432-1444, 2006.
15. Gonzales CR; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. *Retina* 2005;25:815-827.
16. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med* Dec 30;351:2805-2816, 2004.
17. Maguire M; Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). *Ophthalmology* 111:1307-1316, 2004.
18. Complications of Age-related Macular Degeneration Prevention Trial Study Group. The Complications of Age-related Macular Degeneration Prevention Trial (CAPT): rationale, design, and methodology. *Clinical Trials* 1:91-107, 2004.
19. Azab M, Benchaboune M, Blinder KJ, et al; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. *Retina* 2004;24:1-12.
20. Singerman LJ, Miller DG. Pharmacological treatments for AMD. *Rev Ophthalmol* 10: 88-90, 92, 94; 2003. [http://www.revophth.com/index.asp?page=1\\_422.htm](http://www.revophth.com/index.asp?page=1_422.htm)
21. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L, Zilliox P; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. *Ophthalmology* 110:2372-2383, 2003.
22. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EK, Yannuzzi L, Zilliox P; The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. *Retina* 23:14-23, 2003.
23. The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Phase II study results. *Ophthalmology* 110:979-986, 2003.

24. Singerman LJ, Miller DG. Diabetic retinopathy and DME drug trials advance. *Rev Ophthalmol* 10:124-127, 2002. [http://www.revophth.com/index.asp?page=1\\_204.htm](http://www.revophth.com/index.asp?page=1_204.htm)
25. Miller DG, Singerman LJ. The natural history of choroidal neovascularization in high myopia. *Current Opinion in Ophthalmology* 12:222-224, 2001.
26. Martidis A, Miller DG, Ciulla RP, Moorthy RS. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. *Journal of Ocular Pharmacology and Therapeutics* 15:425-428, 1999.
27. Miller DG, Lou PL, Kroll AJ, Ryan EA. Surgical management of macular hole. *International Ophthalmology Clinics* 39:261-274, Winter 1999.
28. Miller DG, Ryan EA. Removal of silicone oil. [Letter] *VitreoTech*, Volume 3, June 1998.
29. Miller DG, Evans R, Blaustein A. Does hydrogen peroxide mediate changes in stunned myocardium? *Clinical Research*, Volume 39, April 1991.

### **Book Chapters**

1. Miller DG, Sharma MC, Singerman LJ. Laser treatment of age-related macular degeneration. In Boyd BF, Boyd S (eds.). *Retinal and Vitreoretinal Surgery: Mastering the Latest Techniques*. Panama: Highlights of Ophthalmology Press, 2005, pp. 250-261.
2. Miller DG, Singerman LJ. Key questions for a focused history. In Steidl SM, Hartnett ME (eds.). *Clinical Pathways in Vitreoretinal Disease*. New York: Thieme, 2003, pp 3-12.
3. Miller DG, Singerman LJ. Laser treatment of age-related macular degeneration. In Boyd BF, Boyd S (eds.). *Retinal and Vitreoretinal Surgery: Mastering the Latest Techniques*. Panama: Highlights of Ophthalmology Press, 2002, pp 249-261.
4. Miller DG, Singerman LJ. Diabetic retinopathy: medical considerations. In Saer JB (ed.). *Vitreo-Retinal and Uveitis Update. Proceedings of the New Orleans Academy of Ophthalmology Symposium*. The Hague: Kugler Publications, 1998, pp 239-244.

### **Abstracts**

1. Brown CC, Miller DG. Results of surgical management of senile macular holes by 25-gauge trans-conjunctival sutureless vitrectomy. *American Society of Retina Specialists Meeting Abstracts*; 2006; <http://www.asrs.org/meetings/abstracts/2006/>.
2. Federman JL, Martidis A, Nelson ML, Belmont JB, Sivalingam A, Miller DG. Intravitreal triamcinolone for refractory diabetic macular edema. *Macula Society Meeting Abstracts*, 2002, p 32.
3. Nelson ML, Martidis A, Miller DG, Spinak DJ, Federman JL. Intravitreal triamcinolone acetone injection for refractory pseudophakic cystoid macular edema. *Retina Congress 2002 Abstracts*, <http://www.vitreoussociety.org/sf2002/index.html>

4. Blade KA, Martidis A, Nelson ML, Belmont JB, Miller DG, Ansari I, Sivalingam A. Intravitreal triamcinolone injection for the treatment of macular edema secondary to branch retinal vein occlusion. *Retina Congress 2002 Abstracts*, <http://www.vitreoussociety.org/sf2002/index.html>
5. Martidis A, Nelson ML, Baker B, Duker JS, Reichel E, Rogers AH, Federman JL, Sivalingam A, Belmont JB, Miller DG. Intravitreal triamcinolone for refractory diabetic macular edema. *Retina Congress 2002 Abstracts*, <http://www.vitreoussociety.org/sf2002/index.html>

### **Posters**

1. Brown CC, Miller DG. Results of surgical management of senile macular holes by 25-gauge trans-conjunctival sutureless vitrectomy. Scientific Poster 4641/B976, Association for Research in Vision and Ophthalmology Annual Meeting, May 2006.
2. Prenner JL, Thompson JT, Miller DG, Saran BR, Gordon JF, Brucker AJ, Reich SJ. An open label study for the evaluation of tolerability of five dose levels of intravitreal VEGF siRNA (Cand5) in patients with wet age-related macular degeneration. Scientific Poster 4632, American Academy of Ophthalmology Annual Meeting, October 2005.
3. Sharma MC, Miller DG, Zakov ZN, Pendergast SD, Novak MA, Zegarra H, Singerman LJ. Results of the surgical management of idiopathic epiretinal membrane. Scientific Poster 472, American Academy of Ophthalmology Annual Meeting, October 2005.
4. Spinak DJ, Martidis A, Miller DG. Intravitreal triamcinolone acetate injection for refractory pseudophakic cystoid macular edema. Scientific Poster 129, American Academy of Ophthalmology Annual Meeting, October 2002.